HBP:CC - Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
(TheNewswire)
April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, today announcedthe appointment of ThomasMehrling, MD, PhD as Chief Executive Officer( “CEO” ) of the Company. A sharpening of Helix’s leadershipstructure, outgoing CEO, JacekAntas , will dedicate his focus to his role asChairman of the Company, and Dr. Mehrling, who has shaped Helix’sclinical strategy in his capacity as Chief Medical Officer( “CMO” ), takes the helm to deliver on the Company’s ambitiousclinical milestones planned for 2025 and beyond.
A distinguished Hemato-Oncologist and Pharmacologistwith over 20 years of experience in pharmaceutical oncology, Dr.Mehrling has a proven track record of building successful, globaloncology businesses and delivering transformative therapies to themarket. As a key architect of Mundipharma International Ltd.’sEuropean oncology business, Dr. Mehrling served as Head of BusinessDevelopment (2000–2004), European Director of Oncology (2004-2011),and International Director of Oncology Strategy (2011-2013),introducing groundbreaking cancer drugs across Europe that achievedsales nearing USD 1 billion (DepoCyte® and Levact®, Ribomustin® andTreanda®). In 2013, he led the establishment and took the helm ofMundipharma EDO GmbH, a Swiss-based start-up within the MundipharmaGroup dedicated to the development of highly selective inhibitors andtargeted medicines for hematological malignancies and solid tumors. In2019, he founded Laevoroc Medical AG, a privately held, Swiss oncologycompany, whose asset acquisition by Helix laid the foundations for abroader strategic collaboration between Dr. Mehrling and the Company.Prior to his tenure at Mundipharma, Dr. Mehrling served as Senior VicePresident of global CRO Medical Affairs at Staticon International, andas Medical Leader at Takeda European R&D Center. Before his transition to the pharmaceutical industry, Dr.Mehrling spent 13 years as an MD at the University Hospital inFrankfurt, where he earned his MD degree from the Department ofInternal Medicine (Hemato-oncology and Cardiology) and his PhD inPharmacology.
Dr. Mehrling, CEO of Helix, said “It’s something I’ve said before, andit’s worth repeating: Helix’s commitment to confronting cancer’smost urgent challenges, with smart innovation and rapiddecision-making, is a cause I am deeply aligned with—and one I amhonored to now lead as CEO. We plan to enter L-DOS47 withpembrolizumab into a Phase II study this year for the treatment ofnon-small cell lung cancer, with other clinical milestones to followin 2026. We are currently preparing to close a financing deal thatwill enable us to launch the execution of this plan and to add topminds to our growing world-class team. It’s ambitious, and we aredetermined to deliver—patients have waited long enough.”
Chairman JacekAntas added, “As Helix moves into its nextphase of growth, we are laser-focused on building a resilient andagile internal organization to deliver on our ambitious roadmap.Thomas’ leadership and experience are exactly what the Company needsat this important juncture, and I look forward to working closely withhim and the rest of our team to achieve our shared goals.”
About Helix BioPharma Corp.
Helix BioPharma is an oncology company shaping a nearfuture where today’s hard-to-treat cancers are made vincible bynovel therapies that rise to the challenge. The Company innovates from strength to tackle cancer’s biggest, mosturgent challenges with a diverse pipeline of drug candidates withgreat potential and a head start, honed into first- and best-in-classoncology medicines. Its pipeline is spearheaded by a clinical-stageproprietary technology platform of bio-conjugates that score withprecision against prevalent CEACAM6-expressing solid tumors. Its leadcandidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stageantibody-enzyme conjugate (AEC) that neutralizes the microenvironmentof common, hard-to-treat solid tumors, taking the brakes offanti-cancer immunity and delivering a game-changing assist totoday’s front-running anti-cancer therapies. L-DOS47 has completedPhase Ib studies in non-small cell lung cancer (NSCLC), with novelstrategically designed bi-specific ADCs targeting CEACAM6 indiscovery.
Helix is listed on the TSX under the symbol “HBP”,on OTC PINK under the symbol “HBPCD” and on FWB under the symbol“HBP0”. For more information, please visit : https://www.helixbiopharma.com/
For more information, pleasecontact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: +1 857 208 7687
Jacek Antas, Director
Forward-Looking Statements and Risksand Uncertainties
This news release contains certainstatements regarding Helix BioPharma Corp. that constituteforward-looking statements and information (collectively, “forwardlooking statements”) as defined by Canadian securities laws.Forward-looking statements are statements and information that are nothistorical facts but instead include statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to its CEACAM6 platform,L-DOS47 and new asset transactions that Helix intends to close.Forward-looking statements can further be identified by the use offorward-looking terminology such as “will”, “plans”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements areintended to provide information about management’s current plans andexpectations regarding future operations and may not be appropriatefor other purposes. Certain material factors, estimates or assumptionshave been applied in making forward-looking statements in this newsrelease. The Company’s actual results could differ materially fromthose anticipated in the forward-looking statements contained in thisnews release as a result of numerous known and unknown risks anduncertainties, including the risk factors discussed in the Company’scontinuous disclosure record filed under the Company’s profile onSEDAR+ at www.sedarplus.ca from time to time. Forward-looking statements and information arebased on the beliefs, assumptions, opinions and expectations ofHelix’s management on the date of this new release, and the Companydoes not assume any obligation to update any forward-looking statementor information should those beliefs, assumptions, opinions orexpectations, or other circumstances change, except asrequired.
Copyright (c) 2025 TheNewswire - All rights reserved.